| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Ataluren |
| Brand | Translarna® |
| Indication | For the treatment of DMD resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing. |
| Assessment Process | |
| Rapid review commissioned | 18/11/2014 |
| Rapid review completed | 23/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 29/10/2015 |
| NCPE assessment completed | 29/04/2016 |
| NCPE assessment outcome | Reimbursement not Recommended |
The HSE has approved reimbursement following confidential price negotiations, May 2019.
